iThemba Pharmaceuticals (Pty) Ltd forms part of WIPO Re:Search

On 26 October 2011, the World Intellectual Property Organization (WIPO), in a collaboration with leading pharmaceutical companies and BIO Ventures for Global Health (BVGH), launched WIPO Re:Search, a new consortium where public and private sector organizations share valuable intellectual property (IP) and expertise with the global health research community to promote development of new drugs, vaccines, and diagnostics to treat neglected tropical diseases, malaria, and tuberculosis.  iThemba is a potential participant in this new consortium.

iThemba Pharmaceuticals (Pty) Ltd  Awarded Centre of Excellence Status for Medicinal Chemistry by the African Network for Drugs and Diagnostics Innovation (ANDI).

iThemba’s critical role in pharmaceutical innovation recognised by  ANDI

At its recent annual stakeholders meeting in Addis Ababa, Ethiopia the African Network for Drugs and Diagnostics Innovation (ANDI) awarded iThemba Pharmaceuticals the prestigious centre of excellence status for medicinal chemistry, the only such centre in Africa.

Click here for more information

iThemba contributes editorial to Future Medicinal Chemistry special edition on neglected  diseases

iThemba CSO, Dr Chris Edlin, features in a special edition of Future Medicinal Chemistry with an editorial on the importance of patent sharing in neglected disease drug discovery. 

Click here for full article

             Flow chemistry validation aimed at improved ARV production

Research-based pharmaceuticals developer iThemba Pharmaceuticals has sent one of its scientists, Dr Darren Riley, to the University of Cambridge to vali- date the use of a new production technique,called continuous flow chemistry, in ultimately producing frontline HIV medicines for South Africa, says iThemba Pharmaceuticals chief scientific officer Dr Chris Edlin.